Lucknow News Flash

The Head and Neck cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Head and Neck cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Head and Neck cancer Market.

Some of the key takeaways from the Head and Neck cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Head and Neck cancer treatment therapies with a considerable amount of success over the years. 
• Head and Neck cancer companies working in the treatment market are Cellectar Biosciences, Inc., Memgen, Inc., Ikena Oncology, Tiglate QBiotics Group Limited, BioNTech, GlaxoSmithKline, Hoffmann-La Roche, Merck, and others, are developing therapies for the Head and Neck cancer treatment 

• Emerging Head and Neck cancer therapies in the different phases of clinical trials are- CLR 131, MEM-288, IK 175, Tigilanol, BNT 113, Niraparib, Atezolizumab, Xevinapant, and others are expected to have a significant impact on the Head and Neck cancer market in the coming years.   
• In October 2022, A randomized, double-blind, placebo-controlled, two-arm Phase III trial was started by Merck KGaA with the goal of evaluating the safety and effectiveness of Xevinapant and radiation therapy in comparison to placebo and radiation therapy in order to show improvement in disease-free survival in patients with resected squamous cell carcinoma of the head and neck who are at high risk of relapse and are not eligible for high-dose cisplatin (XRAY VISION).”
• In March 2021, The Swedish biotech company Debiopharm International and the German pharmaceutical giant Merck have inked a licensing agreement for the global development and commercialization of Debiopharm’s late-stage asset, Debio 1143 (xevinapant), in head and neck squamous cell carcinoma (HNSCC).

Head and Neck cancer Overview

Cancers that originate in the head and neck area are referred to as head and neck cancers. The squamous cells lining the mucosal surfaces of the head and neck—such as those inside the mouth, throat, and voice box—are typically the site of the cancers generally referred to as head and neck cancers.

Get a Free Sample PDF Report to know more about Head and Neck cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight

Emerging Head and Neck cancer Drugs Under Different Phases of Clinical Development Include:

• CLR 131: Cellectar Biosciences, Inc.
• MEM-288: Memgen, Inc.
• IK 175: Ikena Oncology
• Tigilanol: Tiglate QBiotics Group Limited
• BNT 113: BioNTech
• Niraparib: GlaxoSmithKline
• Atezolizumab: Hoffmann-La Roche
• Xevinapant: Merck

Head and Neck cancer Route of Administration

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Head and Neck cancer Molecule Type

Head and Neck cancer Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Head and Neck cancer Pipeline Therapeutics Assessment

• Head and Neck cancer Assessment by Product Type
• Head and Neck cancer By Stage and Product Type
• Head and Neck cancer Assessment by Route of Administration
• Head and Neck cancer By Stage and Route of Administration
• Head and Neck cancer Assessment by Molecule Type
• Head and Neck cancer by Stage and Molecule Type

DelveInsight’s Head and Neck cancer Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Head and Neck cancer product details are provided in the report. Download the Head and Neck cancer pipeline report to learn more about the emerging Head and Neck cancer therapies

Some of the key companies in the Head and Neck cancer Therapeutics Market include:

Key companies developing therapies for Head and Neck cancer are – Eli Lilly and Company, Sanofi, Merck & Co., Inc., Clinigen Group plc., Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd., Coherus BioSciences, and others.

Head and Neck cancer Pipeline Analysis:

The Head and Neck cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Head and Neck cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck cancer Treatment.
• Head and Neck cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Head and Neck cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Head and Neck cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Head and Neck cancer drugs and therapies

Head and Neck cancer Pipeline Market Drivers

• Increase in the prevalence of Head and Neck cancer, robust pipeline, technological breakthroughs in cancer screening processes are some of the important factors that are fueling the Head and Neck cancer Market.

Head and Neck cancer Pipeline Market Barriers

• However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Head and Neck cancer Market growth.

Scope of Head and Neck cancer Pipeline Drug Insight    

• Coverage: Global
• Key Head and Neck cancer Companies: Cellectar Biosciences, Inc., Memgen, Inc., Ikena Oncology, Tiglate QBiotics Group Limited, BioNTech, GlaxoSmithKline, Hoffmann-La Roche, Merck, and others
• Key Head and Neck cancer Therapies: CLR 131, MEM-288, IK 175, Tigilanol, BNT 113, Niraparib, Atezolizumab, Xevinapant, and others
• Head and Neck cancer Therapeutic Assessment: Head and Neck cancer current marketed and Head and Neck cancer emerging therapies
• Head and Neck cancer Market Dynamics: Head and Neck cancer market drivers and Head and Neck cancer market barriers 

Request for Sample PDF Report for Head and Neck cancer Pipeline Assessment and clinical trials

Table of Contents

1. Head and Neck cancer Report Introduction

2. Head and Neck cancer Executive Summary

3. Head and Neck cancer Overview

4. Head and Neck cancer- Analytical Perspective In-depth Commercial Assessment

5. Head and Neck cancer Pipeline Therapeutics

6. Head and Neck cancer Late Stage Products (Phase II/III)

7. Head and Neck cancer Mid Stage Products (Phase II)

8. Head and Neck cancer Early Stage Products (Phase I)

9. Head and Neck cancer Preclinical Stage Products

10. Head and Neck cancer Therapeutics Assessment

11. Head and Neck cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Head and Neck cancer Key Companies

14. Head and Neck cancer Key Products

15. Head and Neck cancer Unmet Needs

16 . Head and Neck cancer Market Drivers and Barriers

17. Head and Neck cancer Future Perspectives and Conclusion

18. Head and Neck cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services